ClinicalTrials.gg
CompletedNCT02766621Updated Nov 17, 2017

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

A Phase 1 interventional study of PF-06823859 and Placebo injection SC/IV in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of escalating single and multiple intravenous (IV) infusions and subcutaneous (SC) injections of PF 06823859 in healthy subjects.

02

Conditions studied

  • Healthy

Keywords

  • First in human, Phase 1, Healthy volunteers
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female subjects of non and male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead or clinical laboratory tests.
  2. (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion criteria

Exclusion Criteria:

  1. History of active or latent tuberculosis (TB) regardless of treatment; positive Quantiferon - TB test.
  2. Subjects with a history of disorders.
  3. Subjects with a history of or positive results for any of the following serological tests: surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), anti antibody (HCVAb) or (HIV).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Placebo comparator
    Placebo injection SC/IV

    Placebo for injection SC/IV

    Drug: Placebo injection SC/IV

  • Active comparator
    PF-06823859

    Study Drug being used in the study

    Biological: PF-06823859

Interventions

  • BiologicalPF-06823859

    Comparison of different dosages of PF-06823859 to placebo

    Also known as: Study drug

  • DrugPlacebo injection SC/IV

    Comparison of Placebo to different doses of PF-06823859

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs

    Safety

    Time frame: Dosing through approximately Day 189

Secondary outcomes

  1. Apparent Clearance (CL) of PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  2. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  3. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  4. Number of Participants With Anti-Drug Antibody (ADA) to PF-06823859

    Immunogenicity

    Time frame: Pre dose to approximately Day 189

  5. Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  6. Maximum Observed Plasma Concentration (Cmax) of PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  7. Plasma Decay Half-Life (t1/2)

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  8. Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06823859 administered subcutaneously

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  9. Volume of Distribution at Steady State (Vss) of PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  10. AUCtau (dose normalized)

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  11. C av of PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  12. Mean residence of time for PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  13. Maximum Observed Plasma Concentration (Cmax) dose normalized of PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

  14. bioavailability of PF-06823859 subcutaneous doses compared to intravenous doses of PF-06823859

    Pharmacokinetics

    Time frame: Pre dose to approximately Day 189

07

Study locations

1 site
  • Pfizer New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
08

References and documents

Publications

  • Neelakantan S, Oemar B, Johnson K, Rath N, Salganik M, Berman G, Pelletier K, Cox L, Page K, Messing D, Tarabar S. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon beta Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study. Clin Pharmacol Drug Dev. 2021 Mar;10(3):307-316. doi: 10.1002/cpdd.887. Epub 2020 Dec 22. PubMed 33352008 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Aug 2017, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2016
First posted
May 10, 2016
StartActual
May 27, 2016
Primary completionActual
Aug 30, 2017
CompletionActual
Sep 26, 2017
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02766621
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 10, 2016
Start date
May 27, 2016
Primary completion
Aug 30, 2017
Completion
Sep 26, 2017
Last update
Nov 17, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazukibart

Start the discussion